TY - JOUR
T1 - Bacterial cancer therapy
T2 - A turning point for new paradigms
AU - Mayakrishnan, Vijayakumar
AU - Kannappan, Priya
AU - Tharmalingam, Nagendran
AU - Bose, Rajendran J.C.
AU - Madheswaran, Thiagarajan
AU - Ramasamy, Mohankandhasamy
N1 - Funding Information:
The authors would like to acknowledge Masonic Medical Research Institute, Utica, New York, the USA for the 2021 Halfond-Weil Postdoctoral Award, and the University of Waterloo, Canada, for extending support.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/8
Y1 - 2022/8
N2 - Cancer treatments have advanced considerably in recent years, appreciably enhancing the quality of life and survival of cancer patients. However, standard cancer treatments still have limitations that must be improved. In recent years, bacteria-based cancer therapy has gained much more attention owing to its unique properties that are unachievable with standard therapeutics. Bacteria species such as Salmonella, Clostridium, and Listeria have been shown to control tumor growth with improved prognosis in experimental animal models and clinical settings.
AB - Cancer treatments have advanced considerably in recent years, appreciably enhancing the quality of life and survival of cancer patients. However, standard cancer treatments still have limitations that must be improved. In recent years, bacteria-based cancer therapy has gained much more attention owing to its unique properties that are unachievable with standard therapeutics. Bacteria species such as Salmonella, Clostridium, and Listeria have been shown to control tumor growth with improved prognosis in experimental animal models and clinical settings.
KW - Anticancer
KW - Bacterial-mediated
KW - Engineered bacteria
KW - Payload delivery
KW - Tumor microenvironment
KW - Tumor targeting
UR - http://www.scopus.com/inward/record.url?scp=85127331677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127331677&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2022.03.007
DO - 10.1016/j.drudis.2022.03.007
M3 - Short survey
C2 - 35304339
SN - 1359-6446
VL - 27
SP - 2043
EP - 2050
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -